Results of Phase I Study Reach Primary End Point for mCRPC
Scott T. Tagawa, MD, MS, discusses a phase I dose-escalation study of actinium-225 in patients with progressive metastatic castration-resistant prostate cancer who had previously received at least 1 pathway inhibitor.
Scott T. Tagawa, MD, MS, professor of Medicine and Urology, and medical director of Genitourinary Oncology Research Program at Weill Cornell Medicine, discusses a phase I dose-escalation study of actinium-225 (225Ac-J591) in patients with progressive metastatic castration-resistant prostate cancer who had previously received at least 1 pathway inhibitor (NCT03276572).
The investigators of this trial did not reach a maximum tolerated dose, according to Tagawa. The study had 7 cohorts, and in 6 out of the 7, 1 patient had grade 4 anemia and thrombocytopenia. In the next cohort, none of the 6 patients had dose-limiting toxicities (DLTs), which were defined as grade 4 hematologic toxicity or grade 3/4 non-hematologic toxicity. Since none of these patients had DLTs, the study authors concluded that there was no maximum tolerated dose defined for this therapy. That cohorts received 93.3 KBq/kg which is now the recommended phase II dose.
Some adverse events that were not DLTs occurred with this therapy, such as grade 3 anemia in 1 patient and the rest were grade 1 and 2 toxicities.
<< View more resources and information regarding prostate cancer
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
FPI-2265 Dosing Commences in Phase 2 AlphaBreak Trial for mCRPC
May 10th 2024The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.
Read More
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen
